{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:09:27Z","timestamp":1778962167796,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.euo.2026.04.012","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:26:49Z","timestamp":1778880409000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline Frailty, Treatment Intensity, and Clinical Outcomes Among Older Adults with Locally-advanced Prostate Cancer"],"prefix":"10.1016","author":[{"given":"Agustin","family":"Perez-Londono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-674X","authenticated-orcid":false,"given":"Jamil","family":"Almohtasib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumedh","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruslan","family":"Korets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aria F.","family":"Olumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Garnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Gershman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.04.012_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.04.012_b0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2021.07.010","article-title":"High-risk locally advanced prostate cancer: multimodal treatment is the key","volume":"38","author":"Terlizzi","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.04.012_b0015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.04.012_b0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.04.012_b0025","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.04.012_b0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eururo.2012.03.053","article-title":"Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised Phase 3 trial","volume":"62","author":"Mottet","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.012_b0035","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1200\/JCO.2014.57.7510","article-title":"Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer","volume":"33","author":"Mason","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.04.012_b0040","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.2014.57.2743","article-title":"Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer","volume":"33","author":"Bekelman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.04.012_b0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.300.2.173","article-title":"Survival following primary androgen deprivation therapy among men with localized prostate cancer","volume":"300","author":"Lu-Yao","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2026.04.012_b0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2014.10.018","article-title":"Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer","volume":"68","author":"Sammon","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.012_b0055","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/phar.2168","article-title":"Risks of major long\u2010term side effects associated with androgen\u2010deprivation therapy in men with prostate cancer","volume":"38","author":"Nguyen","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.euo.2026.04.012_b0060","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijrobp.2016.06.2445","article-title":"Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: results from the DART 01\/05 randomized Phase 3 trial","volume":"96","author":"Zapatero","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2026.04.012_b0065","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrclinonc.2014.71","article-title":"Challenges of managing elderly men with prostate cancer","volume":"11","author":"Jha","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.euo.2026.04.012_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1281432","article-title":"Unraveling the safety of adjuvant radiotherapy in prostate cancer: impact of older age and hypofractionated regimens on acute and late toxicity - a multicenter comprehensive analysis","volume":"13","author":"Buwenge","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2026.04.012_b0075","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.04.012_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2022.104651","article-title":"Impact of frailty on survivals of prostate cancer patients treated with radiotherapy","volume":"100","author":"Pan","year":"2022","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.euo.2026.04.012_b0085","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","article-title":"The prevalence and outcomes of frailty in older cancer patients: a systematic review","volume":"26","author":"Handforth","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.04.012_b0090","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.euo.2026.04.012_b0095","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/gerona\/gly197","article-title":"Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study","volume":"74","author":"Kim","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.euo.2026.04.012_b0100","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2026.04.012_b0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.urology.2020.01.039","article-title":"Emulating target clinical trials of radical nephrectomy with or without lymph node dissection for renal cell carcinoma","volume":"140","author":"Bacic","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.euo.2026.04.012_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111767","article-title":"Emulating an existing trial of treatments for prostate cancer using real-world data: challenges and lessons learned","volume":"182","author":"Chesang","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euo.2026.04.012_b0115","doi-asserted-by":"crossref","first-page":"8207","DOI":"10.1038\/s41598-024-54976-z","article-title":"Androgen deprivation alone versus combined with pelvic radiation for adverse events and quality of life in clinically node-positive prostate cancer","volume":"14","author":"Lee","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2026.04.012_b0120","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1002\/cncr.30948","article-title":"Receipt of definitive therapy in elderly patients with unfavorable\u2010risk prostate cancer","volume":"123","author":"Yang","year":"2017","journal-title":"Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:49:31Z","timestamp":1778960971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":24,"alternative-id":["S2588931126001227"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.012","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline Frailty, Treatment Intensity, and Clinical Outcomes Among Older Adults with Locally-advanced Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}